BT
Breye Therapeutics
Denmark · Biotech
Breye Therapeutics develops oral medicines for retinal diseases.
Product
Breye Therapeutics is a Danish clinical-stage biotechnology company developing oral treatments for retinal diseases. Its lead candidate, danegaptide, is being developed for non-proliferative diabetic retinopathy.
The company is preparing a randomized Phase 2 study of danegaptide and developing other retinal disease candidates, including a P2X7 receptor antagonist for intermediate age-related macular degeneration.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | €67.5M | Mission BioCapital — LeadNovo Holdings — LeadCatalyze Capital — ParticipantDanish Export and Investment Fund (EIFO) — ParticipantInnovestor Life Science — ParticipantLjungström family office — ParticipantModi Ventures — ParticipantPappas Capital — ParticipantSound Bioventures — Participant | |
| Seed | €4M | Novo Holdings — LeadSound Bioventures — Lead |